S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 14.54 USD -0.41% Market Closed
Market Cap: 178.1m USD

SWK Holdings Corp
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SWK Holdings Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
S
SWK Holdings Corp
NASDAQ:SWKH
PP&E Net
$48k
CAGR 3-Years
-80%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
LM Funding America Inc
NASDAQ:LMFA
PP&E Net
$19.8m
CAGR 3-Years
5%
CAGR 5-Years
132%
CAGR 10-Years
N/A
A-Mark Precious Metals Inc
NASDAQ:AMRK
PP&E Net
$32.4m
CAGR 3-Years
25%
CAGR 5-Years
24%
CAGR 10-Years
36%
FlexShopper Inc
NASDAQ:FPAY
PP&E Net
$10.6m
CAGR 3-Years
14%
CAGR 5-Years
15%
CAGR 10-Years
49%
California First Leasing Corp
OTC:CFNB
PP&E Net
$765.6k
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
S
Standard Premium Finance Holdings Inc
OTC:SPFX
PP&E Net
$242k
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

SWK Holdings Corp
Glance View

Market Cap
177.6m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
14.05 USD
Overvaluation 3%
Intrinsic Value
Price
S

See Also

What is SWK Holdings Corp's PP&E Net?
PP&E Net
48k USD

Based on the financial report for Dec 31, 2024, SWK Holdings Corp's PP&E Net amounts to 48k USD.

What is SWK Holdings Corp's PP&E Net growth rate?
PP&E Net CAGR 5Y
-48%

Over the last year, the PP&E Net growth was -99%. The average annual PP&E Net growth rates for SWK Holdings Corp have been -80% over the past three years , -48% over the past five years .

Back to Top